相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Phase Ib Study of Alpelisib (BYL719), a PI3K alpha-Specific Inhibitor, with Letrozole in ER+/HER2(-) Metastatic Breast Cancer
Ingrid A. Mayer et al.
CLINICAL CANCER RESEARCH (2017)
Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A new Light in the Darkness
Jordi Rodon et al.
CANCER DISCOVERY (2017)
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
Dejan Juric et al.
CANCER DISCOVERY (2017)
Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy
Wennan Zhao et al.
ACTA PHARMACEUTICA SINICA B (2017)
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies
Sinead Toomey et al.
BREAST CANCER RESEARCH (2017)
Sensitivity to lapatinib differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA and relies on production of PIP3
J. P. Garay et al.
CANCER RESEARCH (2017)
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S. Loibl et al.
ANNALS OF ONCOLOGY (2016)
PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2-advanced breast cancer (BC): First results from the randomized, phase Ill BELLE-2 trial
J. Baselga et al.
CANCER RESEARCH (2016)
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Jose Baselga et al.
CLINICAL CANCER RESEARCH (2016)
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
Martine Piccart-Gebhart et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer
Xiuning Le et al.
CANCER DISCOVERY (2016)
Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer
Sandrine Tury et al.
ONCOTARGET (2016)
Role of Akt signaling in resistance to DNA-targeted therapy
Abolfazl Avan et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2016)
New approaches for improving outcomes in breast cancer in Europe
Angelo Di Leo et al.
BREAST (2015)
Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer
Carlotta Costa et al.
CANCER CELL (2015)
Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ
Sarit Schwartz et al.
CANCER CELL (2015)
PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer
Ian J. Majewski et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Deciphering the Role of Phosphatidylinositol 3-Kinase Mutations in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Shom Goel et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
HER2-family signalling mechanisms, clinical implications and targeting in breast cancer
N. Elster et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Dejan Juric et al.
NATURE (2015)
Suppression of Feedback Loops Mediated by PI3K/mTOR Induces Multiple Overactivation of Compensatory Pathways: An Unintended Consequence Leading to Drug Resistance
Enrique Rozengurt et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer
L-Y Huw et al.
ONCOGENESIS (2013)
PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab
J. D. Jensen et al.
ANNALS OF ONCOLOGY (2012)
Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
Celina Garcia-Garcia et al.
CLINICAL CANCER RESEARCH (2012)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Jose Baselga et al.
LANCET (2012)
PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups
Magdalena Cizkova et al.
BREAST CANCER RESEARCH (2012)
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
E. Razis et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer
Jose Baselga
ONCOLOGIST (2011)
PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality
Elena Lopez-Knowles et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
Katherine Stemke-Hale et al.
CANCER RESEARCH (2008)
Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
Pieter J. A. Eichhorn et al.
CANCER RESEARCH (2008)
Tenets of PTEN tumor suppression
Leonardo Salmena et al.
CELL (2008)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women
Naomi Maruyama et al.
CLINICAL CANCER RESEARCH (2007)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
Mutant PIK3CA promotes cell growth and invasion of human cancer cells
Y Samuels et al.
CANCER CELL (2005)
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma
LH Saal et al.
CANCER RESEARCH (2005)
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
SY Kang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
分享论文
